Fatty Acid-Binding Protein 4 and Major Adverse Cardiovascular Events: A Dose-Response Meta-Analysis of Prospective Cohort Studies
Clicks: 1
ID: 314059
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #138 of 194 articles by views in european journal of preventive cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
AIMS: To quantify the association between circulating fatty acid-binding protein 4 (FABP4) levels and the risk of major adverse cardiovascular events (MACE) and secondary cardiovascular outcomes in prospective cohort studies. METHODS AND RESULTS: We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to 1 December 2025 for prospective cohort studies evaluating baseline FABP4 levels in relation to subsequent cardiovascular outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models, and dose-response analyses were performed. Thirty-five prospective cohort studies were included (PROSPERO: CRD420261291090). In the pooled analysis, participants in the highest FABP4 category, as defined within each study, had a 61.6% higher risk of MACE than those in the lowest category (HR = 1.616, 95% CI: 1.402-1.863; I2 = 35.0%). This association remained significant when FABP4 was analysed as a continuous variable (HR = 1.393, 95% CI: 1.181-1.643; I2 = 79.9%). Higher FABP4 levels were also associated with higher risks of secondary cardiovascular outcomes, including cardiovascular death, heart failure, and myocardial infarction. In linear dose-response analyses, each 10 ng/mL higher baseline FABP4 level was associated with a 16.6% higher risk of MACE and a 13.1% higher risk of cardiovascular death, with no evidence of non-linearity. Sensitivity analyses yielded similar results, and no substantial publication bias was detected for the primary MACE analysis. CONCLUSION: Higher FABP4 levels were associated with higher risks of MACE and cardiovascular death, supporting its potential relevance as a prognostic marker warranting further evaluation.
| Reference Key |
openalex_W7161633517
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yanjie Jiang, Shipeng Zhang, Man Lu, Hanyu Wang, Xingyi He, Zhihui Jin, Rui Fu, Xuran Cao, Qinwei Fu, Wenshan Li, Xiaoyu Zhu, Qinxiu Zhang, Xin Sun, Yan Lu |
| Journal | european journal of preventive cardiology |
| Year | 2026 |
| DOI |
10.1093/eurjpc/zwag276
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.